

## *Declaration letter*

Dear Sir/Madame who might be concerned,

20 Feb 2023

We, GC Biopharma Corp., previously known as Green Cross Corporation, hereby declare that the 2023-2024 Northern Hemisphere strains which will be recommended by WHO for the composition of influenza virus vaccine for use in the 2023-2024 Northern Hemisphere influenza season, will be used for the production of GCFLU Quadrivalent Pre-filled syringe inj. in 2023-2024 NH.


The applied CPP can be issued by July 2023, from the Ministry of Food and Drug Safety (MFDS) after strain change approval in Republic of Korea.

Sincerely,



---

**Yunchul Shin**  
Head of Regulatory Affairs II Team  
GC Biopharma Corp.



The document contains confidential and proprietary information. It should not be copied or disclosed to any third party without the written permission of GC Biopharma Corp.. The document shall be used for registration/regulatory purpose only and must be reviewed and approved with correspondent date and signature prior to release.